Simlukafusp alfa

欣洛奇芙普

Report date: 2023/02/22 20:00:32

Base Information

Drug NameSimlukafusp alfa
Drug Alias NameRG-7461FAP-IL2vaFAP-IL2vRO-6874281FAP-IL2v FP
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionFibroblast activation protein alpha antagonistsInterleukin-2 receptor beta chain agonistsInterleukin-2 receptor subunit gamma agonists
TargetsProlyl endopeptidase FAPInterleukin-2 receptor beta chainInterleukin-2 receptor subunit gamma
Therapy Area/IndicationsSolid tumoursUterine Cervical NeoplasmsHead and Neck Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[20] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursHead and Neck NeoplasmsBreast Neoplasms +[5] 
Inactive IndicationsUterine Cervical NeoplasmsEsophageal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A